Literature DB >> 15212723

Cost-effectiveness in Preventive Cardiology.

William S. Weintraub1.   

Abstract

Cardiovascular disease remains a serious medical problem, which can be associated with death and disability on one hand, and considerable resource utilization on the other. The primary driver for choice of therapy must remain clinical efficacy. Once efficacy is established, cost-effectiveness analysis has an important role. Resources are limited, and responsible choices must be made. The methods involved in cost-effectiveness analysis are complicated and data for the analysis are generally not fully optimal. Nonetheless, cost-effectiveness analysis offers the best method for helping society make rational medical decisions. Effective interventions, when reasonably priced, for the prevention of cardiovascular disease have generally proven to be cost-effective.

Entities:  

Year:  2004        PMID: 15212723     DOI: 10.1007/s11936-004-0030-7

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  48 in total

Review 1.  The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.

Authors:  N F Woolacott; L Jones; C A Forbes; L C Mather; A J Sowden; F J Song; J P Raftery; P N Aveyard; C J Hyde; P M Barton
Journal:  Health Technol Assess       Date:  2002       Impact factor: 4.014

Review 2.  Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage.

Authors:  K E Warner
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

3.  Principles involved in costing.

Authors:  D B Evans
Journal:  Med J Aust       Date:  1990-08-06       Impact factor: 7.738

Review 4.  The use of QALYs in health care decision making.

Authors:  G Loomes; L McKenzie
Journal:  Soc Sci Med       Date:  1989       Impact factor: 4.634

5.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

6.  Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  JAMA       Date:  1996-11-06       Impact factor: 56.272

7.  Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.

Authors:  R A Hayward; W G Manning; S H Kaplan; E H Wagner; S Greenfield
Journal:  JAMA       Date:  1997-11-26       Impact factor: 56.272

8.  State-specific prevalence among adults of current cigarette smoking and smokeless tobacco use and per capita tax-paid sales of cigarettes--United States, 1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1998-11-06       Impact factor: 17.586

9.  Cost-benefit analysis of walking to prevent coronary heart disease.

Authors:  T F Jones; C B Eaton
Journal:  Arch Fam Med       Date:  1994-08

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.